POST-MARKETING ADVERSE EVENTS (AES) ASSOCIATED WITH TETRABENAZINE (TBZ): FINDINGS USING FDA'S ADVERSE EVENT REPORTING SYSTEM (FAERS)

被引：0

作者：

Claassen, Daniel O. ^{[1
]}

Iyer, Ravi ^{[2
]}

Dimbil, Mo ^{[3
]}

Giron, Abril ^{[3
]}

De Boer, Lisa ^{[4
]}

Gandhi, Sanjay ^{[2
]}

Hoffman, Keith B. ^{[3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Teva Pharmaceut Ind, Frazer, PA USA

[3] Advera Hlth Analyt, Santa Rosa, CA USA

[4] Teva Pharmaceut, La Jolla, CA USA

来源：

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2016年 / 87卷

关键词：

D O I：

10.1136/jnnp-2016-314597.206

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

I41

引用

页码：A73 / A73

页数：1

共 50 条

[41] Reports of adverse events related with second generation antipsychotics in children in the FDA adverse event reporting system (FAERS)
Zapata, Lorenzo Villa
Bibbs, Janese
Crapps, Mariah
Lumbreras, Ainhoa Gomez
Malone, Daniel
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 579 - 580
[42] Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
Li, Yun
Li, Hang
Xiang, Zhongyuan
[J]. HELIYON, 2024, 10 (06)
[43] Assessing taxane-associated adverse events using the FDA adverse event reporting system database
Lao, Dong-Hui
Chen, Ye
Fan, Jun
Zhang, Jian-Zhong
[J]. CHINESE MEDICAL JOURNAL, 2021, 134 (12) : 1471 - 1476
[44] Contact dermatitis adverse events: A review of contact dermatitis-associated reports from the FDA adverse event reporting system (FAERS)
Taylor, J. S.
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S42 - S42
[45] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
Jow, Steven
Hutfless, Susan
[J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
[46] A REALWORLD PHARMACOVIGILANCE STUDY OF FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) EVENTS FOR EMPAGLIFLOZIN AND DAPAGLIFLOZIN
Milutinovic, Stefan
Petrovic, Marija
Jancic, Predrag
Trajkovic, Hristina
Alarcon, Ricardo Orlando Escarcega
Chazal, Richard A.
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 319 - 319
[47] Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system
Li, Huqun
Wang, Chongshu
Guo, Cuilian
[J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
[48] Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
Liu, Yan-xin
Dong, Chang-jiang
He, Xu-cheng
Shu, Ya-min
Wu, Pan
Zou, Jian
[J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2022, 25 : 377 - 390
[49] A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
Zou, Wenbin
Yang, Han
Xi, Yu
Zeng, Chenxi
Chen, Wei
Fu, Xiangning
[J]. HELIYON, 2024, 10 (17)
[50] Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
Bao, Yiwen
Chen, Jiaju
Duan, Luting
Wang, Fujue
Lai, Han
Mo, Zeming
Zhu, Weiliang
[J]. FRONTIERS IN PHARMACOLOGY, 2024, 15

← 1 2 3 4 5 →